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Abstract
Background: Care for most people with schizophrenia is best delivered in the community and evidence-based
guidelines recommend combining both medication and a psychosocial intervention, such as community-based
rehabilitation. There is emerging evidence that community-based rehabilitation for schizophrenia is effective at
reducing disability in middle-income country settings, yet there is no published evidence on the effectiveness in
settings with fewer mental health resources. This paper describes the protocol of a study that aims to evaluate the
effectiveness of community-based rehabilitation as an adjunct to health facility-based care in rural Ethiopia.
Methods: This is a cluster randomised trial set in a rural district in Ethiopia, with sub-district as the unit of
randomisation. Participants will be recruited from an existing cohort of people with schizophrenia receiving
treatment in primary care. Fifty-four sub-districts will be randomly allocated in a 1:1 ratio to facility-based care plus
community-based rehabilitation (intervention arm) or facility-based care alone (control arm). Facility-based care
consists of treatment by a nurse or health officer in primary care (antipsychotic medication, basic psychoeducation
and follow-up) with referral to a psychiatric nurse-led outpatient clinic or psychiatric hospital when required. Trained
community-based rehabilitation workers will deliver a manualised community-based rehabilitation intervention, with
regular individual and group supervision. We aim to recruit 182 people with schizophrenia and their caregivers.
Potential participants will be screened for eligibility, including enduring or disabling illness. Participants will be recruited
after providing informed consent or, for participants without decision-making capacity, after the primary caregiver
gives permission on behalf of the participant. The primary outcome is disability measured with the 36-item WHO
Disability Assessment Schedule (WHODAS) version 2.0 at 12 months. The sample size will allow us to detect a 20 %
difference in WHODAS 2.0 scores between treatment arms with 85 % power. Secondary outcomes include change in
symptom severity, economic activity, physical restraint, discrimination and caregiver burden.
Discussion: This is the first trial of community-based rehabilitation for schizophrenia and will determine, as a proof of
concept, the added value of community-based rehabilitation compared to facility-based care alone in a low-income
country with scarce mental health resources.
Trial registration: Clinical Trials.gov Identifier NCT02160249. Registered on 3 June 2014.
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Background
Schizophrenia can be a severe, chronic and disabling
condition, which places a high social and economic bur-
den on individuals [1], families [2] and society. The major-
ity of people with schizophrenia in sub-Saharan Africa do
not have access to adequate care [3]. Over half of the
people with schizophrenia in Ethiopia experience continu-
ous or episodic illness over a 10-year period [4], where the
treatment gap is estimated to be 90 % [5, 6]. Mortality is
high; the standardised mortality ratio for people with
schizophrenia in Ethiopia is twice that of the general
population [7]. People with schizophrenia are also likely to
experience stigma and discrimination [8, 9] and human
rights violations [10].
According to global consensus, supported by scientific
review of the evidence and the experience of mental
health system experts, a comprehensive mental health sys-
tem includes both community- and hospital-based com-
ponents of care [11, 12] and should incorporate both
medication and psychosocial interventions [13, 14]. Rela-
tively low-intensity psychosocial community-based pro-
grammes, which are likely to be most feasible, have been
shown to be effective in low- and middle-income country
(LMIC) settings [15–17]. To date such programmes have
typically involved four groups: the patient, family mem-
bers, a community-based non-specialist key worker and a
psychiatrist [14]. In particular, the World Health Organi-
sation’s (WHO’s) mental health Gap Action Programme
(mhGAP) recommends community-based rehabilitation
(CBR) as an adjunct to medication for schizophrenia [18].
CBR is a general approach with the aim to improve the
quality of life and social inclusion of people with disabil-
ities [19] and is typically delivered by trained lay workers
from the local community. Key pillars of a CBR
programme include interventions that promote health,
education, livelihood, and social life. In addition there is a
cross-cutting emphasis on empowerment, such as support-
ing people with disabilities to make their own decisions.
CBR is put into practice through the joint endeavours of
people with disabilities, their caregivers, community mem-
bers and relevant governmental and non-governmental
services, including health services [20].
CBR programmes have traditionally focussed on people
with physical disabilities. There is increasing recognition
that people with mental disorders may also receive benefit
from a service model that integrates mental health and
economic development [21, 22]. CBR may impact on clin-
ical and disability outcomes in people with schizophrenia
by improving understanding of the illness, increasing ad-
herence to antipsychotic medication, reducing stigma and
improving social functioning.
Globally there are a few examples of CBR programmes
for people with mental disorders [17, 23–30]. A systematic
review found that CBR may improve clinical outcomes
and functioning for schizophrenia, dementia and intellec-
tual disabilities in LMICs [20]. However, no randomised
controlled trials (RCTs) of CBR for schizophrenia that in-
volved community mobilisation (defined as ‘a strategy
which aims to engage community members and empower
them for change or action’ [19]), or focussed primarily on
any CBR pillar other than health, were included [20]. Fur-
thermore, there were no studies set in countries defined
by the World Bank as being low-income [20]. The more
recent COmmunity care for People with Schizophrenia in
India (COPSI) trial [31], a study from India (a middle-
income country), found that collaborative community care
modestly improved disability and symptoms in people
with schizophrenia [17]. The greatest effects were seen in
rural areas with fewer formal mental health resources.
Whilst influenced by CBR, the intervention did not in-
clude community mobilisation, and participants had ac-
cess to psychiatrists as a key component of care.
To our knowledge there has been no previous rando-
mised trial investigating the impact of a comprehensive
CBR programme, including both home-based care and
a structured community mobilisation element, on out-
comes in people with schizophrenia. Furthermore, the
effectiveness of CBR for schizophrenia has not previ-
ously been examined in a low-income setting, such as
Ethiopia, which has minimal formal mental health re-
sources. Currently, most people with schizophrenia in
rural Ethiopia will never have access to a psychiatrist,
psychiatric nurse or other mental health professional.
However, mental health care is being scaled up in
Ethiopia by training general health workers, largely in
primary care, to deliver care for people with mental dis-
orders. This process illustrates the Ethiopian Ministry of
Health’s efforts to improve access to mental health care
[32].
Extensive formative research using a variety of
methods nested within a Theory of Change framework
has enabled the design of a culturally and contextually
appropriate CBR intervention for people with schizo-
phrenia that is acceptable and feasible to service users
and providers in rural Ethiopia [33, 34]. The CBR inter-
vention, which includes home-based care, community
mobilisation and family support groups, has been
piloted. This paper presents the protocol for the Re-
habilitation Intervention for people with Schizophrenia
in Ethiopia (RISE) project, a cluster randomised trial,
which will evaluate the effectiveness of this CBR
intervention.
Objectives
Primary objective
To evaluate the effectiveness of CBR as an adjunct to
facility-based care (FBC), compared to FBC alone, in re-
ducing disability related to schizophrenia at 12 months,
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measured by the WHO Disability Assessment Schedule
(WHODAS) version 2.0 in patients with evidence of
poor response or lack of engagement in care over the
preceding 6 months.
Secondary objectives
1. To evaluate the effectiveness of CBR plus FBC
compared to FBC alone in reducing clinical
symptoms, reducing relapse, increasing medication
adherence, improving economic activity, reducing
physical restraint, reducing discrimination, and
improving nutritional status in people with
schizophrenia.
2. To evaluate the effectiveness of CBR plus FBC
compared to FBC alone in reducing family burden,
stigma and depression, and improving economic
activity in caregivers of people with schizophrenia
3. To explore the acceptability and feasibility of CBR
from the perspective of (1) those receiving the
treatment, (2) their families, and (3) those delivering
the treatment.
4. To determine the cost-effectiveness of CBR plus
FBC compared to FBC alone.
5. To investigate the process through which CBR
achieves its impact.
Primary hypothesis
People with schizophrenia who receive CBR in addition
to FBC will experience greater reductions in disability
compared to those who receive only FBC, to the order
of 20 % absolute difference in WHODAS 2.0 score be-
tween groups, over a 12-month period.
Methods
Study design
The design is a cluster randomised controlled trial with
sub-district (pre-defined administrative unit consisting
of several villages together) as the unit of randomisation.
The study flow chart is presented in Fig. 1. From 58
sub-districts in the study district, four sub-districts were
sites for the pilot and the remaining 54 sub-districts will
be included for the actual trial; 27 will be randomly allo-
cated to the intervention arm (FBC plus CBR) and 27
Fig. 1 RISE flow chart
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randomly allocated to the control arm (FBC alone). In
total, 182 participant dyads (patients and their caregivers)
will be recruited. On average there will be 3.4 participant
dyads per sub-district.
Cluster randomisation is the chosen method of ran-
domisation because first, CBR includes community-level
elements and family support groups, based on sub-
districts, so individual randomisation is not possible; sec-
ond, it is logistically more convenient to concentrate
CBR workload in fewer sub-districts; and third there is
increased acceptability if all participants in a sub-district
are allocated to either intervention or control arms. This
paper follows the Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) recommenda-
tions for trial protocols (see Additional file 1).
Setting
The trial will take place in Sodo district, Gurage Zone,
Southern Nations, Nationalities and Populations Region
(SNNPR) in Ethiopia. The administrative town of Sodo,
Bui, lies 100 km from Addis Ababa. Sodo district has a
population of 170,000 persons in 58 sub-districts: four
urban and 54 rural. Most people live in one-room mud
and straw houses and work as subsistence farmers.
About 45% of the population are literate and the major-
ity are Orthodox Christian by religion.
There is a psychiatric nurse-led outpatient clinic at the
general hospital in Bui. There is a similar unit at Butajira
hospital, which is 30 km away from Bui in the neigh-
bouring district. Primary health care is delivered through
eight primary health care centres staffed by health offi-
cers and general nurses. Each health centre oversees
between four and 11 health posts, staffed by two health
extension workers (HEWs). Each health post covers a
sub-district, with a population of 2800–5000 people.
Health care costs are largely out-of-pocket with a free
waiver available for the poorest; in practice a tiny minor-
ity of the population are likely to be in receipt of this
waiver.
Context of the study
The RISE trial is nested in PRIME (PRogramme for Im-
proving Mental healthcarE). PRIME is a multicountry re-
search consortium that aims to generate evidence on the
implementation and scaling up of packages of care for
priority mental disorders in primary health care in
LMICs [35, 36]. As part of the PRIME project, a com-
prehensive mental health care plan was developed for
Ethiopia [37–39] and, from December 2014, facility-
based care for schizophrenia was embedded in primary
health care centres in Sodo district. Health officers and
nurses were trained in the detection and treatment of
schizophrenia, including the prescription of anti-
psychotic medication and psychoeducation. Training
followed the WHO’s mhGAP and evidence-based guide-
lines [18, 40], adapted for the Ethiopian context. PRIME
identified people with schizophrenia in Sodo using the
Butajira key informant method [41] and, from December
2014, began following up those invited to access FBC in
a 12-month treatment cohort. A subsample of the
PRIME cohort participants will be recruited to the RISE
trial at the PRIME 6-month data collection. The ration-
ale for recruiting into the trial after participants have
had 6 months access to FBC is that if this intervention
were scaled up in a resource-poor setting such as
Ethiopia, it would only be made available for those with
enduring illness or poor treatment outcomes.
Interventions
Facility-based care
FBC will be available to all participants in the RISE trial.
The frequency of contact with FBC will be determined
by clinical need. Within formal health care, FBC is a
three-tier system, but the majority of care will be deliv-
ered at tier 1, which is primary care (Table 1).
Community-based rehabilitation
Intervention development
The CBR intervention was constructed through in-depth
intervention development work as described in detail
elsewhere [34, 42]. The work included a literature re-
view, situational analysis [43, 44], an intervention devel-
opment workshop, participatory meetings, qualitative
interviews with a range of stakeholders, including people
with schizophrenia, their caregivers, psychiatrists and
community leaders, and collaboration with an existing
CBR project, RAPID (Rehabilitation And Prevention Ini-
tiative against Disabilities). RAPID is an Ethiopian CBR
project for children with disabilities.
CBR worker recruitment and training
Eleven CBR workers were recruited according to the cri-
teria: (1) completed tenth grade education (secondary
school), (2) resident in Sodo district, and (3) interest in
community work. Training lasted for 5 weeks and com-
prised an equal split of classroom teaching and field
work, including home visits to people with schizophrenia
and on-the-job training at RAPID. Psychiatrists and CBR
trainers from RAPID delivered the training. Competency
was assessed using role-plays and patient vignettes.
Pilot
A 12-month pilot was conducted. The pilot included ten
people with schizophrenia and their families living in
four sub-districts not involved in the main trial. The
aims of the pilot were to determine the acceptability and
feasibility of the CBR intervention and to refine the
intervention and trial design as needed. Major
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adjustments to the intervention and trial design were
made prior to the trial starting. Minor adjustments may
be made to the latter components of the CBR interven-
tion on the basis of pilot findings.
Trial CBR delivery
One or two CBR workers will be attached to each health
centre and each will cover two or three sub-districts.
Each CBR worker will have approximately eight people
with schizophrenia under their care. The delivery of
CBR for schizophrenia will be the only task for the CBR
workers. CBR delivery will commence immediately after
recruitment into the trial and will continue for
12 months. The CBR visits will take place at the partici-
pants’ home and last 30–90 minutes. The intervention is
delivered in three phases (Table 2). In phase 1, lasting 2
to 3 months, there are weekly home visits and the focus
is on engagement with the family and addressing core
needs through compulsory modules such as ‘Under-
standing Schizophrenia’. In phase 2, lasting approxi-
mately 5 to 6 months, home visits are every 2 weeks and
address the specific needs of the individual through op-
tional modules such as ‘Getting Back to Work’. In phase
3, lasting approximately 4 months, the emphasis is on
preventing relapse as well as maintaining the progress
made towards addressing specific needs. CBR workers
conduct community mobilisation work and may run
family support groups alongside the home visits. The de-
tailed content of CBR at each phase of the intervention
is described in Table 1. Flexibility will be encouraged ac-
cording to the needs of the individual participant and
their caregiver. CBR delivery will be guided by a manual
that outlines steps for the delivery of each module and
community engagement task, procedures for referral
and how to deal with difficult situations, for example,
suicidal ideation. Two supervisors will maintain an over-
view of the frequency, content and quality of the home
visits by CBR workers for each participant. Supervision
will include monthly unannounced observed sessions,
with individual face-to-face supervision and group
supervision every 2 to 4 weeks. Unannounced visits will
take place only with the prior permission of participants.
The trial coordinator will attend group supervision
monthly and conduct a paper-based review of all cases
every 2 weeks with each supervisor. The coordinator will
ensure the on-going fidelity of CBR delivery and guide
top-up training sessions for CBR workers where
required.
Selection and randomisation of clusters
We will aim to include all 54 sub-districts in Sodo dis-
trict (after excluding the four pilot sub-districts). The
randomisation of sub-districts into CBR plus FBC and
FBC arms will be stratified by health centre. A minimisa-
tion algorithm [45] will be employed to ensure balance
for (1) urban/rural location, (2) number of potential
participants (i.e. cases of schizophrenia in the PRIME
cohort) in the sub-district, and (3) mean WHODAS 2.0
score in the sub-district at PRIME cohort baseline. All
these factors may potentially impact on the primary out-
come. PRIME cohort baseline WHODAS 2.0 scores will
only provide an estimate of the disability level of poten-
tial participants as this data will not be available for the
entire pool of trial participants and will not represent
disability levels at the time of recruitment. The alloca-
tion sequence will be generated randomly from the set
of optimal sequences [46]. An independent statistician
will generate the allocation list for sub-districts. This list
Table 1 Facility-based care three-tier system for the treatment of mental illness
Location Staff Tasks Referral
Tier 1: primary care
Eight health centres across
Sodo district
Health officers
and nurses
• Prescribe antipsychotic medication (oral haloperidol
or chlorpromazine) and monitor response
• Manage side-effects
• Monitor suicide risk
• Review physical health
• Screen for substance misuse
• Provide basic psychoeducation
(information about schizophrenia)
• Provide regular follow-up
• Refer to tier 2 in the following scenarios:
o Active suicidal intent
o Inadequate oral intake of fluid or food
o Risk of violence to others and/or risk
of serious self-neglect
o Persistently non-adherent to medication
o Acutely disturbed and not
manageable at home
o Pregnancy/breastfeeding
o Medical complications
o Unmanageable side-effects
Tier 2: general secondary care
Psychiatric outpatient clinic at
Butajira Hospital
Psychiatric nurse • Specialist review
• Initiate depot injection where required
• Refer to tier 3 when inpatient care is
required
• Refer back to tier 1 for follow-up
Tier 3: specialist care
Ammanuel Psychiatric
Hospital, Addis Ababa
Psychiatrist • Specialist review
• Inpatient admission where required
• Refer back to tier 1 and/or tier 2 for
follow-up
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is will be kept securely by the trial coordinator and uti-
lised to determine allocation status of new recruits.
Participant inclusion criteria
There are no specific exclusion criteria. Participants
must meet all of the following criteria to be included: (1)
be a participant in the PRIME cohort study or not en-
gaged in FBC but resident in Sodo district, (2) have been
resident in the sub-district for more than 6 months and
have no immediate plans to leave the sub-district, (3)
have a primary caregiver who is willing to participate in
the study, (4) be aged 18 years older, (5) have a diagnosis
of schizophrenia spectrum disorder (schizophrenia, schi-
zoaffective disorder or schizophreniform disorder) using
Diagnostic and Statistical Manual of Mental Disorders,
version four (DSM-IV) [47] criteria, and (6) have evi-
dence of enduring or disabling illness demonstrated by
one or more of the following: (a) Brief Psychiatric Rating
Scale – Expanded version (BPRS-E) score ≥52 (equiva-
lent to at least ‘moderately ill’ on the Clinical Global Im-
pression (CGI) scale) [48], (b) 36-item WHODAS 2.0
score ≥35, (c) have continuous illness over the preceding
6 months, as assessed using the Life Chart Schedule
(LCS), (4) be symptomatic in 3 out of the last 6 months,
as assessed using the LIFE chart, or (e) have a CGI
score ≥3 (at least ‘mildly ill’). The final criterion allows
us to include the group expected to benefit the most
from CBR and also reflects the threshold at which CBR
could realistically be offered in this resource-constrained
setting.
Participant flow
Participant identification
PRIME aimed to detect all people with schizophrenia in
Sodo by training key informants (HEWs and community
leaders) to identify possible cases. This method was suc-
cessful at identifying people with psychosis in previous
Ethiopian studies, including in the neighbouring district
[41, 49, 50]. Possible cases of schizophrenia were invited
to their health centre for diagnosis and treatment. If they
attended, a psychiatric nurse conducted a diagnostic
interview using the OPCRIT (Operational Criteria for
Table 2 RISE community-based rehabilitation (CBR) intervention outline
Phase Months Visits CBR activities
Assessment and family
engagement
Community mobilisation Family-level interventions
1: Intensive
engagement
~1–3 Weekly • Developing therapeutic
alliance with family
• Needs assessment
• Risk assessment
• Goal setting for phase 1
• Rehabilitation plan
• Resource mapping for sub-district, e.g.
churches, schools, edir groups (traditional
burial association), Women’s Association,
literacy groups, religious groups and
traditional healers
• Initial awareness-raising and mobilisation,
targeting health extension worker,
community leaders and traditional healers
• Awareness raising meeting/s with general
public in sub-district
Core modules:
• Understanding schizophrenia
• Improving access to health care
• Dealing with human rights issues
• Preparing for a crisis
2: Stabilisation ~4–8 Fortnightly • Update needs assessment
• Risk assessment
• Goal setting for phase 2
• Update rehabilitation plan
• Facilitate access to relevant community
resources
• Consolidate mobilisation and awareness
raising
Optional modules:
• Supporting individuals to take
medication
• Improving the family environment
(coping skills, marital problems)
• Improving day-to-day functioning
• Taking part in community life
• Getting back to work
• Dealing with distressing symptoms
• Dealing with stigma and discrimination
• Improving physical health
• Dealing with stress and anger
• Improving literacy
• Family support groups
• Taking control of your illness (relapse
prevention and management)
3: Maintenance ~9–12 Monthly • Update needs
assessment
• Risk assessment
• Goal setting for phase 3
• Update rehabilitation
plan
• Prepare for termination
• Continuing care
assessment
• Consolidate access to community
resources
• Consolidate awareness raising and
mobilisation
Core module:
• Taking control of your illness (relapse
prevention and management) if not
completed in phase 2Optional
modules
• Any of the phase 2 modules
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Research), an operational criteria checklist for psychotic
and affective illness [51, 52]. The OPCRIT facilitated the
nurse to determine if participants had a DSM-IV diagno-
sis. Substantial inter-rater reliability and convergent valid-
ity of the OPCRIT has been demonstrated in other
settings [53] and there is good experience of using
OPCRIT in a clinical trial of schizophrenia in the neigh-
bouring district [54]. All confirmed cases of schizophrenia
spectrum disorders were offered FBC and, where they
consented, were recruited into the PRIME cohort. Prior to
RISE recruitment a psychiatrist conducted an additional
paper-based diagnosis review of all PRIME cohort partici-
pants using the clinical instruments completed at baseline,
including the OPCRIT. Where the psychiatrist deemed
the diagnosis unclear, a repeat clinical assessment by the
psychiatric nurse will be completed prior to RISE
recruitment.
Participant recruitment
Participants for the RISE trial will be primarily recruited
from people who were identified and received a diagno-
sis of a schizophrenia spectrum disorder at the baseline
of the PRIME cohort and their caregivers, and were liv-
ing in the sub-districts selected to participate in the
RISE trial. However, we will recruit from up to four
pools of potential participants, known as recruitment
levels.
Level 1 recruitment comprises recruitment from the
PRIME cohort at the 6-month data collection interview,
which takes place at the health centre. Level 2 recruit-
ment comprises recruitment from PRIME cohort drop-
outs, i.e. those who do not attend the PRIME 6-month
data collection. Level 3 recruitment comprises recruit-
ment from those who were identified by key informants
but have never attended FBC. This group had some
baseline data collected through a home visit by PRIME
as part of a non-engagement study. Level 4 recruitment
comprises recruitment from those individuals who were
identified by key informants as potential cases with
schizophrenia after the recruitment for the PRIME co-
hort had ended. Level 1 recruitment will take place at
consecutive pairs of health centre catchment areas, de-
termined by the PRIME data collection schedule. For
levels 2, 3 and 4 recruitment, all sub-districts will be
covered equally to avoid unequal recruitment by treat-
ment arm. RISE recruitment will take place either at the
health centre at PRIME data collection or at a follow-up
visit at the participant’s home.
The aim of incorporating non-PRIME cohort partici-
pants is that these non-engagers in care are likely to
have more complex needs, and be more symptomatic
and disabled. They are, therefore, the individuals who
are likely to receive the most benefit from CBR. Some of
these individuals will not be accessing care because they
are currently well, and will be excluded from the trial
using the standard recruitment criteria.
Within each CBR worker area, the transition from one
recruitment level to the next will continue until approxi-
mately eight participants have been recruited for each
CBR worker. The aim is to ensure CBR workers have
equal workloads, to ensure CBR delivery is as uniform
as possible. If it is not possible to recruit eight partici-
pants in any particular CBR worker area (after exhaust-
ing all recruitment levels), recruitment will continue at
other CBR worker areas whilst aiming to keep the num-
ber of participants per CBR worker as equal as possible.
Recruitment will proceed to the next recruitment level/s
until a maximum of 12 participants per CBR worker are
recruited. This is because the maximum feasible workload
for CBR workers is expected to be 12 participants. There
may be slight adjustments to the number of participants
recruited per CBR worker depending on drop-out of CBR
workers or other unforeseen factors.
Recruitment procedures
The recruitment procedures for each of these groups
will be detailed in dedicated Standard Operating Proce-
dures (SOPs). Potential participants in the PRIME co-
hort will have their eligibility for the RISE trial checked
by the trial coordinator or trial nurse using PRIME 6-
month data (i.e. WHODAS 2.0, BPRS-E, CGI, LIFE
chart and LCS). Eligible participants will be invited to
join the RISE trial by a trial nurse. They will be given in-
formation about the trial in a way appropriate to the
participants’ literacy level, which may include verbal in-
formation. The trial nurse will then conduct the consent
procedures.
Participants not in the PRIME cohort will have an initial
consent taken, before data is collected on the eligibility in-
struments, including the diagnostic interview. Those who
are eligible will then be consented to take part in the RISE
trial. Those who consent (or, for those without decision-
making capacity, whose caregiver consents on their be-
half) will complete the full RISE baseline data collection.
Allocation
The randomisation of sub-districts to intervention and
control arms will take place before recruitment. The ra-
tionale is that it is necessary to commence delivery of
the CBR intervention immediately after recruitment.
The trial coordinator will keep the sub-district allocation
list secure on a password-protected document. To re-
duce selection bias, the potential participant will not be
informed of the allocation of their sub-district until after
they have consented to participate and all baseline data
collection is complete. The trial nurse will also be blind
to the allocation. The trial coordinator will assign a
unique trial identifier (ID) to each new participant and
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Table 3 Summary of outcome measures
Outcome Instrument
Psychiatric nurse-administered interview with patient
Symptom severity Brief Psychiatric Rating Scale – Expanded version (BPRS- E) [62]. A 24-item instrument
focussing on psychotic symptoms, but also covering somatic concerns, anxiety,
depression and mania. Individual BPRS-E items and total score are sensitive to change
in persons with persistent schizophrenia [63]. The scale has been previously used in
Ethiopia [64] and has recently been shown to have good inter-rater reliability (>0.8
comparing psychiatric nurses and psychiatrists) in this setting (personal communication,
Dr Charlotte Hanlon) [65]. As the scale is clinician-rated this allows for sociocultural
sensitivity. Inter-rater and test-retest reliability as well as internal consistency are also
high in high-income settings [66]
Clinical impression Clinical Global Impression (CGI). A widely used assessment tool, comprising three
scales, to determine overall illness severity and efficacy of intervention [67]
Relapse Life Chart Schedule (LCS) including course type and relapses [68].
Longitudinal Interval Follow-up Evaluation: DSM-IV version (LIFE). A semi-structured
interview to determine the subject’s psychiatric course since the last interview [69].
Satisfactory validation has been conducted in Ethiopia and the reliability data is
currently being analysed. Any necessary adjustments will be made on the basis of
the inter-rater reliability assessments (personal communication, Dr Girmay Medhin)
Lay data collector-administered interview with the patient
Disability Patient-reported 36-item WHODAS (Disability Assessment Schedule) 2.0 [55].
A validated indigenous functioning scale, specific to the Ethiopian context [70]
Economic activity Measure covering current employment, subsistence farming work, income, and
hunger due to lack of resources
Discrimination Section 1 of the Discrimination and Stigma Scale-12 (DISC-12) [71]
Medication adherence Adapted Morisky Medication Adherence Scale (MMAS) [72]. This scale has previously
been utilised for antipsychotic medication adherence [31, 73]. Good construct
validity has been demonstrated in Ethiopia (personal communication, Dr Charlotte
Hanlon) [65]).
A 5-point nominal scale measuring frequency of adherence [31]
Health service use and costs including engagement with
FBC for schizophrenia and physical health conditions
An adapted version of The Client Service Receipt Inventory (CSRI) will enquire
systematically about the costs (direct and indirect) of help-seeking from biomedical,
traditional and religious healers [74, 75]. The CSRI has been translated into Amharic
and found to be acceptable and feasible [76]
Access to community interventions (including CBR
components)
Including person administering the component, and satisfaction
Physical restraint In the preceding 1 and 6 months. Includes assessment of duration, perpetrator,
setting and reason for restraint
Nutritional status Measurement of weight (kg) and height (m) will be carried out [77] and body mass
index (weight in kg/(height in m)2) calculated
Depression The Patient Health Questionnaire- 9 (PHQ-9). A 9-item scale which scores each of
the 9 DSM-IV criteria for depressive disorders as ‘0’ (not at all) to ‘3’ (nearly every
day) [78]. Shown to be valid in the Ethiopian setting [79]
Alcohol use disorder The AUDIT (Alcohol Use Disorders Identification Test) is a ten-item tool to detect
hazardous drinking [80]
Social support Oslo-3 Social Support Scale [81]
Serious adverse events Occurrence of serious adverse events (for example, suicide attempt and
hospitalisation for medical emergency) in the last 6 months
Lay data collector interview with the primary caregiver
Patient disability The 36-item WHODAS 2.0 proxy version will assess functional impairment from the
caregiver’s perspective [82, 83]
Economic activity of caregiver Employment, subsistence farming work, income, and hunger due to lack of
resources
Caregiver burden The Burden Section of the WHO ‘Family Interview Schedule’. This scale, covering
financial strain and work difficulties has been previously used in Ethiopia for persons
with schizophrenia [2].
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will determine the allocation of all new recruits using
the secure allocation list. Recruitment and participant
flow will be closely monitored by the trial coordinator
and any protocol deviations recorded and reported.
Outcome assessments
Quantitative
All outcomes are individual-level and will be assessed at
6 and 12 months (Table 3). Baseline RISE data will be
extracted from 6-month PRIME cohort data and 6-
month RISE data will be extracted from 12-month
PRIME cohort data. Twelve-month RISE data will be
collected independently of the PRIME cohort. Trained
lay data collectors will collect all data except for symp-
tom severity, clinical course, overall clinical impression
of illness severity and improvement, and medication, for
which a trained psychiatric nurse will be used. Patient
outcomes will be collected with the caregiver present ac-
cording to participant preference and when the patient
does not have the capacity to answer questions inde-
pendently. Data will be collected directly from the pa-
tient where possible (except for caregiver-reported
outcomes). Items will be recorded as missing in the sce-
nario that the caregiver is not present due to patient re-
fusal, and the patient is unable or unwilling to respond.
Quality will be assured through systematic observations
of data collection by a research assistant (for lay data
collectors) or psychiatrist (for psychiatric nurse data col-
lectors), and by verification of all patient record forms.
Regular meetings will be held to provide feedback to
data collectors.
In order to reduce information bias data collectors will
be masked to sub-district allocation; participants will be
requested not to divulge treatment allocation to data
collectors; participants from different sub-districts will
be allocated to each data collector; identical methods for
follow-up will be employed in each arm; and those in-
volved in data analysis will be masked to sub-district
allocation.
Loss to follow-up will be minimised by reminding par-
ticipants to attend the interview shortly before they are
due, either by telephone or by a home visit. Participants
who do not attend will receive a home visit to ask them
to attend at an alternative time. Data collection will take
place at the health centre except for participants who
do not attend after three invitations. These participants
will receive a home visit for data collection. Partici-
pants will receive a modest fee for transport and time
compensation.
The primary outcome is proxy report of patient dis-
ability which will be measured with the 36-item WHO
DAS (Disability Assessment Schedule) 2.0 [55], through
interviewing the caregiver. WHODAS 2.0 was developed
as single generic instrument for assessing health status
and disability relating to a range of health conditions
across cultures and settings. It covers understanding and
communication, getting around, self-care, getting along
with people, life activities and participation in society.
Sociocultural adaptation and validation (convergent val-
idity, construct validity and responsiveness to change) of
the WHODAS 2.0 in persons with schizophrenia has
been completed in Ethiopia (personal communication,
Kassahun Habtamu). Issues arising during the adaptation
included items not having obvious direct translations
and representing uncommon experiences in the rural
Ethiopian setting (for example, ‘staying by yourself for a
few days’). These issues were largely resolved through it-
erative adjustments to the translation following piloting.
The proxy WHODAS 2.0 interview is designed to be an-
swered by a friend, relative or carer. The rationale for
using the proxy version for the primary outcome is that
this may give a more valid picture of disability level. A
separate study in the neighbouring district found that
whilst scores from patient- and proxy-reported versions
are moderately correlated, there is a difference, with the
caregiver scores tending to be higher (greater disability)
(personal communication, Kassahun Habtamu). Patients
may not have enough insight to answer accurately and,
therefore, underreport disability. They may also be too
unwell to answer all questions, increasing the amount of
missing data. Table 3 lists the secondary outcomes,
which include patient-reported WHODAS 2.0, symptom
severity, relapse, medication adherence, economic activ-
ity in the patient and caregiver, discrimination, health
service use and costs, physical restraint, nutritional sta-
tus, caregiver burden, caregiver depression and caregiver
Table 3 Summary of outcome measures (Continued)
A scale developed for PRIME will quantify the time burden of caring for their
relative with schizophrenia, the type of work that was stopped or reduced and the
amount of money lost. The Involvement Engagement Questionnaire (IEQ) will be
used as an additional measure to assess caregiver burden.
Caregiver depression PHQ-9 [78, 79]
Stigma Section of the WHO ‘Family Interview Schedule’; previously used in Ethiopia [8]
Patient medication adherence The 5-point nominal scale developed for the COPSI study will be used [31]
CBR community-based rehabilitation, DSM-IV Diagnostic and Statistical Manual of Mental disorders, version four, FBC facility-based care
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stigma. All instruments have been adapted for use in
Ethiopia; further details on validation and reliability are
also given in Table 3.
Process data
Process data will be compiled using a range of sources
to determine the quality and intensity of intervention
delivery. These include (1) CBR worker ‘sub-district’
logbooks, including type and number of community en-
gagement tasks completed, (2) CBR worker ‘participant’
logbooks including home visit forms (modules under-
taken, duration and travel time) and assessment forms,
(3) monthly observation of CBR visits by supervisor and
completion of the ENACT (Enhancing Assessment of
Common Therapeutic factors) rating scale [56] adapted
and validated for the Ethiopian context. The adapted
ENACT assesses communication skills, engagement with
the individual, family and community, assessment of
medication adherence, physical health, substance use
and suicide risk assessment, (4) observation of CBR
home visits by an external clinician (psychiatric nurse or
psychiatrist) to complete the ENACT, providing an inde-
pendent assessment of CBR worker skills, (5) CBR
worker competency assessment by supervisor (rating of
1 to 3 given for each of 47 CBR competencies, e.g. ability
to conduct community awareness raising meeting), (6)
CBR worker self-assessed competency form, (7) super-
visor logbook including number of supervision sessions
attended, (8) health centre records to determine fre-
quency of contact with participant, and (9) participant-
reported structured assessment of the extent to which
CBR met their needs.
Qualitative
In-depth interviews (IDIs) will be conducted at baseline
and 12 months with a sub-sample of patients and care-
givers to gather information on the impact of CBR and
other factors on the experience of illness and recovery.
Around eight to ten participant dyads from each treat-
ment arm will be included depending on when theoret-
ical saturation is reached. After gaining separate
informed consent, interviews will be audio-taped, tran-
scribed in Amharic and then translated into English
prior to conducting a thematic analysis. IDIs will be con-
ducted with four to eight community leaders to under-
stand their role in CBR and their perception of its
potential impact. IDIs and FGDs will be conducted with
CBR workers and supervisors to understand their ex-
perience of delivering CBR and its perceived impact on
participants. One or two focus groups will also be held
with health centre nurses to understand their experience
of working with CBR workers.
Power calculation
We estimate that 182 participant dyads (mean 3.4 partic-
ipants/sub-district) will be available for recruitment. As-
suming that there is 23 % attrition, the final sample size
for analysis will be 140 participant dyads in 54 sub-
districts (mean 2.6 participants/sub-district). This sam-
ple size will allow us to detect a 20 % absolute difference
in WHODAS 2.0 scores between treatment arms with
85 % power and 5 % significance, assuming a k (coeffi-
cient of variation) of 0.14 and a within-cluster standard
deviation (SD) of 16. The value of k was extracted from
symptom severity data by sub-district from an RCT in
Butajira evaluating trimethoprim as an adjuvant treat-
ment for schizophrenia (k = 0.11) [57]. A more conserva-
tive estimate of k has been used to account for the
potential therapist effect; each CBR worker will cover
around three sub-districts and CBR intensity and quality
may differ by CBR worker. The mean WHODAS 2.0 in
intervention and control arms and within-cluster SD
were derived from an Indian study of people with
schizophrenia [58].
The estimate of 182 participant dyads available for re-
cruitment was arrived at using (1) the total adult population
of Sodo district, (2) the local prevalence of schizophrenia
(0.05 %) [59], (3) an estimate that 60 % of cases will be de-
tected and agree to participate in the PRIME cohort, (4)
an assumption that 70 % of cases will be eligible for RISE,
based rates of continuous illness found in a previous study
in the neighbouring district of Butajira [5], and (5) an as-
sumption that approximately 80 % of eligible cases will
agree to participate, based on previous recruitment rates
in the Butajira cohort study [5].
Data management
All data collection and management will follow Good
Clinical Practice (GCP) guidelines and SOPs. Each par-
ticipant has a unique ID that will enable all data re-
ported for each participant to be identified. Blinding will
be maintained during data collection, entry, processing
and primary data analysis. Data is collected on paper
Patient Report Forms (PRF) and double entered onto
electronic Case Report Forms on EpiData Entry Client
(2.0.7.22). Data will be managed using EpiData Data
Manager (2.0.8.56).
All databases will be password-protected and only access-
ible to authorised personnel. Data cleaning based on fre-
quency distributions and logic checks will follow standard
procedures with reference to source documents as required.
The data system is designed to ensure that all data changes
are documented and that there is no undocumented dele-
tion of entered data, i.e. an audit trail will be in place. Sys-
tematic checks will be carried out to ensure that the audit
trail is functioning correctly. Data and all appropriate
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documentation will be stored for a minimum of 5 years
after the completion of the study, including the follow-up
period.
Data analysis
Data analysis will take place using Stata, version 13. The
primary outcome analysis will be masked until the ana-
lysis is finalised and approved by all investigators.
Adequate CBR will be defined as having received a mini-
mum of ten home visits by a CBR worker. We will not
define adequate treatment for the FBC arm a priori.
Sociodemographic and clinical characteristics (including
WHODAS 2.0 score) of eligible PRIME cohort partici-
pants who did and did not consent to RISE will be com-
pared using chi-square tests and t tests. Loss-to-follow-up
will be compared by treatment arm at 6 and 12 months to
assess bias due to loss to follow-up. Of those who en-
rolled, descriptive summaries of sociodemographic and
clinical characteristics, presented by treatment arm, will
be produced for baseline data. CBR worker characteristics
such as age, gender, education level and post-training
competency will be described.
Endpoint data will be analysed under intention-to-
treat assumptions. An individual-level analysis will be
conducted using a multilevel, mixed-effects regression
model to compare the WHODAS 2.0 score between
treatment arms, accounting for clustering at sub-district
and CBR worker levels. The WHODAS 2.0 distribution
will determine the model used. If zero-inflation is de-
tected, a zero-inflated negative binomial model will be
considered [60]. Adjustment will be made for baseline
WHODAS 2.0 score and covariates unbalanced at base-
line. Logistic regression will be used to assess which
baseline variables are associated with missing outcome
data. Baseline variables that predict missing outcome
will be included in the regression models as fixed covari-
ates to meet the assumption that outcome data is miss-
ing at random. Multiple imputation methods will then
be used for participants with missing outcome data.
Sensitivity analyses will include a complete case ana-
lysis and a complier average causal effect (CACE) ana-
lysis [61]. We will also assess whether there is a dose-
response relationship between degree of adherence to
CBR (i.e. number of sessions) and the primary outcome.
A further analysis will be undertaken to understand
which the active components of CBR are. Process data
on which CBR components were received, and in what
quantity, will be utilised. Potential correlations between
different components will be taken into account.
Exploratory sub-group analyses by baseline symptom
severity and antipsychotic medication adherence will
be completed, although the study will not be powered
to investigate such differential effects. A longitudinal
analysis will be conducted using a random-effects
model. Three levels (CBR worker, sub-district and indi-
vidual) and two time points (6 and 12 months) will be
included. Secondary and tertiary outcomes will be ana-
lysed using mixed-effects linear regression models or
logistic regression depending on the data type.
Cost-effectiveness analysis
Direct costs of the treatment will be estimated by deriv-
ing a monetary value for each component of the treat-
ment based on actual costs, and applying these to each
individual based on the process indicators, which reflect
the actual uptake of the treatment. Other health care
costs and other patient- or family-borne costs will be
computed and compared at 6 and 12 months, and sub-
sequently related to changes in disability and clinical
symptoms. Incremental cost-effectiveness ratios will be
calculated to illustrate the extra cost incurred (if any) to
produce a unit improvement in the main outcome of
disability-adjusted life years (DALYs) calculated from the
36-item WHODAS 2.0. In the event that dominance is
not shown, i.e. the intervention is more effective but the
costs are also more than the FBC group, incremental
cost-effectiveness ratios will be computed, together with
their confidence intervals (using bootstrapping tech-
niques to overcome expected skewness of cost data).
Cost-effectiveness acceptability curves will also be derived
in order to show the probability of any cost-effective ad-
vantages for the FBC plus CBR group at a range of ‘will-
ingness to pay’ threshold levels.
The results from the quantitative and qualitative work
will be combined to give an overall assessment of the
intervention effectiveness.
Trial management and monitoring
The trial is sponsored by the London School of Hygiene
and Tropical Medicine. A Data Safety and Monitoring
Board (DSMB) has been convened to assure the con-
tinuing safety of research participants. A clinical monitor
will carry out onsite monitoring visits prior to the trial
commencing, at recruitment, and at 6-month and 12-
month follow-up. The trial coordinator will carry out
day-to-day monitoring and will also review recruitment
rates, withdrawals and losses to follow-up. All protocol
violations will be recorded and included in reports of
trial findings.
Confidentiality
Trial-related assessments will take place in private loca-
tions. A unique ID number will be linked to patient de-
tails in hard and soft copy formats that are kept in
secure locations. Signed consent forms will be kept se-
curely in a locked cupboard. All documentation that in-
cludes patient data will be anonymised, but identifiable
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through the ID number. Names of patients will not be
quoted or published.
Discussion
Human rights violations and the high disability burden
of schizophrenia make the condition a priority area for
public health action. The importance of rehabilitation
services for schizophrenia in scaling up mental health
care is recognised by the WHO [18] and the Ethiopian
government [32]. There is emerging evidence that CBR
for schizophrenia is effective at improving disability out-
comes in middle-income settings, yet there is no evi-
dence on whether CBR can work in a setting with even
fewer mental health resources, such as Ethiopia. The
RISE trial will determine the added value of CBR com-
pared to FBC alone. This will help to determine, for
scaling-up services, the importance of a dedicated re-
habilitation service in addition to FBC.
Trial status
Recruitment complete; trial ongoing.
Additional file
Additional file 1: SPIRIT checklist – RISE trial protocol. A checklist of the
full protocol components according to the SPIRIT criteria. (PDF 106 kb)
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